CNS 5161: Phase IIa data

In a double-blind, placebo-controlled, dose-escalation, crossover, European Phase IIa trial in 48 patients with chronic neuropathic pain, 500 µg CNS 5161 improved pain levels at 2, 6 and 12 hours afte...